Status:

COMPLETED

Effect of Repeated Dosing of Naproxcinod on Renal Hemodynamic and on Sodium Balance in Healthy Volunteers Before and After a Single Dose of Furosemide

Lead Sponsor:

NicOx

Conditions:

Renal Hemodynamics

Eligibility:

MALE

18-35 years

Phase:

PHASE1

Brief Summary

This phase 1 study is an 8-day treatment period, randomized, controlled, double-blind, 3 parallel-groups, monocentric study. The primary objective is to evaluate the effect of naproxcinod on the renal...

Eligibility Criteria

Inclusion

  • Healthy, non smoker male subjects aged 18 and 35 years (inclusive), at the Screening visit.
  • Body Mass Index (BMI) strictly between 18 and 30 kg/m² (inclusive) with body weight≥ 50 kg at the Screening visit.
  • Normal physical examination at the Screening visit.
  • Normal ECG (12-lead) at the Screening visit, as judged by the Investigator.
  • At Screening and run-in period visits , Systolic Blood Pressure (SBP) between 100 and 139 mmHg (inclusive) and Diastolic Blood Pressure (DBP) between 50 and 89 mmHg (inclusive).
  • At Screening and run-in period visits, HR between 45 and 90 bpm (inclusive).
  • Subjects must be able to understand the written information sheet and informed consent and comply with all study requirements.
  • Subjects must provide a written, dated and signed informed consent prior to any study procedure.

Exclusion

  • A history of hypersensitivity reactions (such as asthma, rhinitis, or urticaria) to aspirin, naproxen or any other NSAIDs; or hypersensitivity or contraindications to organic nitrate drugs or hypersensitivity to furosemide or to sinistrine or PAH.
  • Family history of hypertension which may disqualify the subject, as judged by the investigator..
  • History of any clinically relevant gastrointestinal (such as gastritis or gastric ulcer), respiratory, psychiatric, neurologic, kidney, liver, cardiac disease, bleeding disorder, other disease/condition or abnormal physical finding which may interfere with the study objectives. The investigator may disqualify any subject for a sound medical or psychiatric reason.
  • History or presence of ASAT \>40UI/L, ALAT \>40UI/L, serum bilirubin 3 times above the Upper Limit of Normal range at the Screening visit.
  • Creatinine clearance inferior/equal to 80 ml/min as calculated with the Cockcroft-Gault formula (Appendix 5 of the protocol) at the Screening visit.
  • Plasmatic potassium \<3.5 mmole/L at the Screening visit.
  • Seropositivity for HBs, HBc, HIV 1 or HIV 2 at the Screening visit.
  • Donations of blood, plasma or platelets within 3 months prior to the Screening visit or donation planned during the 3 months following Day 8.
  • Any clinically significant abnormal laboratory values at the Screening visit.
  • At the Screening visit, after 1 minute in a standing position, a drop of more than 20 mmHg in SBP or 10 mmHg in DBP or a clinical manifestation of postural hypotension.
  • Chronic use of any drugs (prescription or OTC) within 4 weeks prior to Visit 2 (single use of medication such as paracetamol for headache will be tolerated at the lowest possible dose).
  • Intake of any Nitric Oxide Synthase Inhibitor within 1 month before Screening visit.
  • History of drug addiction or alcohol abuse as defined by DSM IVR, diagnostic criteria for drug and alcohol abuse or drug addiction.
  • Positive drug screening (opiates, cannabinoids, cocaine, benzodiazepines, amphetamines, barbiturates) at the Screening visit.
  • Current participation or participation within 60 days prior to the Screening visit, in another investigational study, including the present study or any previous enrolment in a naproxcinod study.
  • In custody due to an administrative or a legal decision, or under tutelage, or being admitted to a sanitary or social institution.
  • Any direct or indirect involvement with the study conduct or staff at site or any family link with study site staff.

Key Trial Info

Start Date :

January 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2009

Estimated Enrollment :

31 Patients enrolled

Trial Details

Trial ID

NCT00909519

Start Date

January 1 2009

End Date

April 1 2009

Last Update

June 17 2011

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.